Upcoming Events
Join us for Telesis Bio’s lunch & learn event presented by Thien Dinh (field application scientist), and Felice Butler (business development manager). We will introduce you to Telesis Bio Inc. and the BioXp synthetic and molecular biology workstation located at MBC Biolabs in San Carlos.
Capabilities of the BioXp includes the automated building of mRNA, DNA fragments, clones, amplified DNA and variant libraries from either digital sequences or dsDNA templates, as well as NGS library prep for plasmid/genome sequencing.
We will provide an overview of these capabilities and use cases, and introduce you to some exciting new developments involving stable, easy to use, transfection-ready mRNA synthesized on the BioXp.
Telesis Bio has worked with hundreds of clients over the last several years from emerging start-ups to nearly all Top 25 Biopharma companies in a wide range of synthetic biology applications including Antibody Discovery, mRNA Vaccine Discovery, TCR/CAR, etc.
With the BioXp technology, Telesis Bio has empowered researchers to go from digital sequence to expressed proteins in <10 days (Antibodies, TCRs, CARs, target antigens, engineered proteins etc.), skipping the cloning and transduction steps, allowing them to screen biotherapeutic candidates 75-90% faster and with higher throughput than via outsourcing or traditional benchwork, drastically accelerating their hit-to-lead discovery timelines for blockbuster therapeutics.
Discover the secrets to unlocking funding opportunities and accessing essential instruments for your work! Join us for a dynamic Lunch & Learn event hosted by Agilent in partnership with Mission Bay Capital.
Key Topics Include:
Please register below to reserve your spot!
For inquiries, contact flavia.nachbar@mbcbiolabs.com
Don’t miss this chance to gain valuable insights and enhance your funding strategies!
Discover the secrets to unlocking funding opportunities and accessing essential instruments for your work! Join us for a dynamic Lunch & Learn event hosted by Agilent in partnership with Mission Bay Capital.
Key Topics Include:
Please register now to reserve your spot!
For inquiries, contact flavia.nachbar@mbcbiolabs.com
Don’t miss this chance to gain valuable insights and enhance your funding strategies!
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
Please join us for a lunch with Benchling and learn about their R&D data management tools, including the Benchling Life Sciences Cloud (specifically limited to the Benchling Notebook and Molecular Biology applications), along with access to Benchling’s Customer Success Bootcamp for onboarding and training, to resident companies of five or fewer employees.
Please join us for a lunch with Benchling and learn about their R&D data management tools, including the Benchling Life Sciences Cloud (specifically limited to the Benchling Notebook and Molecular Biology applications), along with access to Benchling’s Customer Success Bootcamp for onboarding and training, to resident companies of five or fewer employees.
Learn more about our equipment during our bi-monthly office hours.
Please join us for a lunch with Benchling and learn about their R&D data management tools, including the Benchling Life Sciences Cloud (specifically limited to the Benchling Notebook and Molecular Biology applications), along with access to Benchling’s Customer Success Bootcamp for onboarding and training, to resident companies of five or fewer employees.
Please join Niyati Patel from LiCor Bio for a lunch and learn on topics including detection chemistry impact, Western Blot best practices, assay development tools, image acquisition, data analysis, scientific support and partnership.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
Creating innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy.
Our Speakers
Nicholas T. Hertz, Ph.D.
Founder and CEO at Montara Therapeutics
Nicholas T. Hertz, Ph.D., is the Founder and CEO at Montara Therapeutics, a seed stage biotechnology company. At Montara, he is working with an experienced team to create innovative therapies for diseases of the brain with a focus on genetically validated targets to leverage a platform from the Shokat lab that allows CNS specific targeting to enhance drug safety and efficacy. Dr. Hertz completed a B.S. in Biochemistry from UCLA (magna cum laude) and then pursued a Ph.D. in Chemistry and Chemical Biology at UCSF under Dr. Kevan Shokat where they discovered the first class of PINK1 activating molecules and co-founded Mitokinin. Following postdoctoral research in neuroscience with Dr. Marc Tessier-Lavigne at Stanford University he served as CSO of Mitokinin, taking the research from discovery to the clinic. At Mitokinin, Dr. Hertz’s team developed novel small molecule PINK1 activators that could represent the first disease-modifying therapy for Parkinson’s Disease. Mitokinin was acquired in October, 2023.
Dr. Hertz’s has published over 20 publications in leading journals such as Cell, Neuron, and Nature, and he holds more than 12 patents. His work emphasizes the importance of rigorous science, innovative therapeutic development, and the dynamics of collaborative leadership in advancing our understanding and treatment of neurodegenerative diseases.
Kevan M. Shokat, Ph.D.
Investigator of the Howard Hughes Medical Institute,
Professor in the Department of Cellular and Molecular Pharmacology at the UCSF
Professor in the Department of Chemistry at the UC Berkeley
Kevan M. Shokat is currently an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and Professor in the Department of Chemistry at the University of California at Berkeley. He received his B.A. in Chemistry from Reed College in 1986, his Ph.D. in organic chemistry at UC Berkeley with Professor Peter Schultz and carried out post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow. Kevan’s research group is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases, and RNA helicases. His laboratory utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011), and the American Academy of Arts and Sciences (2011). In 2023 he was awarded the Vollum Prize from Reed College, the National Academy of Sciences Award for Scientific Discovery and the Sjöberg Prize from the Royal Swedish Academy of Sciences for ‘discoveries that enable the inhibition of mutated K-Ras in cancer treatment’ and the Heath Memorial Award Lecture, from MD Anderson Cancer Center. In 2024, he was awarded the Edward E. Smissman Award by the ACS Medicinal Chemistry division and also the Hope Funds Award of Excellence for Basic Science. He has commercialized discoveries from his laboratory through co-founding several biotechnology companies including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines, Erasca and Kumquat Biosciences.
Register:
Please join us for a lunch with Benchling and learn about their R&D data management tools, including the Benchling Life Sciences Cloud (specifically limited to the Benchling Notebook and Molecular Biology applications), along with access to Benchling’s Customer Success Bootcamp for onboarding and training, to resident companies of five or fewer employees.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
Please join our partners at Bio-Rad for a lunch and learn on the latest information regarding Bio-Rad’s instruments, reagents, and analysis solutions for your Cell and Gene Therapy needs. Hear from Bio-Rad’s team of Field Application Scientists while you enjoy free lunch, and actively partake in asking in-depth, technical questions pertaining to your lab’s unique analyses
MBC BioLabs Life Science Vendor’s Showcase May 2024
We are excited to host another Life Science Vendor Showcase on May 22nd at our 930 Brittan Avenue, San Carlos location!
The showcase aims to bring together the latest and greatest in life science technologies and services from a variety of vendors. If you are a Life Science vendor and currently not affiliated with MBC, we’d love to have you!
Please register below. The fee to participate is $1,000.
This is an opportunity for our resident scientists and entrepreneurs to explore cutting-edge tools and services, learn about new techniques, resources, and network with other members of the life science community.
Learn more about our equipment during our bi-monthly office hours.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
MBC’s valued partner, Perkin Elmer Health Sciences (PKI), has transformed into Revvity (RVTY).
With “revolutionize” – rev – and “vita” (“life” in Latin) – vit – being rooted in our new name, Revvity represents commitment to revolutionizing human health at an accelerated speed, embracing the impossible to improve lives everywhere.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, cell counting, screening, detection and diagnosis, informatics, and more.
Dynamic Light Scattering (DLS) has emerged as a valuable technique in biotherapeutic development, offering non-invasive and rapid insights into crucial physical parameters of biomolecules. DLS signal changes are directly correlated to the size distribution and molecular weight of particles in solution. In biopharmaceutical applications, DLS plays a pivotal role in characterizing size, aggregation, and stability (structural and colloidal). In this seminar, we provide an overview of the key principles of DLS and its uses in biotherapeutic development.
Why attend?
• This is an opportunity to get a concise overview of Dynamic Light Scattering
• Learn about the uses of Dynamic Light Scattering in biotherapeutic development
Who should attend?
• Anyone interested in Dynamic Light Scattering and would like a concise overview of the technique including its benefits and limitations
Any questions?
Please contact Kiel Jones, Business Development Manager – Discovery at: kiel.jones@malvernpanalytical.com
